TY - JOUR
T1 - Primary plasma cell leukemia
T2 - consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
AU - Fernández de Larrea, Carlos
AU - Kyle, Robert
AU - Rosiñol, Laura
AU - Paiva, Bruno
AU - Engelhardt, Monika
AU - Usmani, Saad
AU - Caers, Jo
AU - Gonsalves, Wilson
AU - Schjesvold, Fredrik
AU - Merlini, Giampaolo
AU - Lentzch, Suzanne
AU - Ocio, Enrique
AU - Garderet, Laurent
AU - Moreau, Philippe
AU - Sonneveld, Pieter
AU - Badros, Ashraf
AU - Gahrton, Gösta
AU - Goldschmidt, Hartmut
AU - Tuchman, Sascha
AU - Einsele, Hermann
AU - Durie, Brian
AU - Wirk, Baldeep
AU - Musto, Pellegrino
AU - Hayden, Patrick
AU - Kaiser, Martin
AU - Miguel, Jesús San
AU - Bladé, Joan
AU - Rajkumar, S. Vincent
AU - Mateos, Maria Victoria
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
AB - Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
UR - http://www.scopus.com/inward/record.url?scp=85120883552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120883552&partnerID=8YFLogxK
U2 - 10.1038/s41408-021-00587-0
DO - 10.1038/s41408-021-00587-0
M3 - Article
C2 - 34857730
AN - SCOPUS:85120883552
SN - 2044-5385
VL - 11
JO - Blood Cancer Journal
JF - Blood Cancer Journal
IS - 12
M1 - 192
ER -